Immune Checkpoint Inhibitor-Related Pneumonitis

Gomatou, Georgia; Tzilas, Vasilios; Κοττέας, Ηλίας; Syrigos, Konstantinos; Bouros, Demosthenes

doi:10.1159/000509941

Cited by 45 publications

(46 citation statements)

References 96 publications

(112 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common irAEs that require glucocorticoids treatment was checkpoint inhibitor pneumonitis (CIP). The incidence of CIP in our cohort was 11.1%, and 4.8% for severe CIP (grade 3 or above), similar to previous reports (3.5–19%) ( 22 ). In addition, there was a significant correlation between the incidence of CIP and radiotherapy.…”

Section: Discussionsupporting

confidence: 91%

Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China

et al. 2022

View full text Add to dashboard Cite

BackgroundPatients treated with immunotherapy in the real-world may have significantly different responses to those meeting inclusion criteria for random controlled clinical studies. There is a partial overlap in approved indications for the use of the different immune checkpoint inhibitors (ICIs) currently available. A comprehensive assessment of the efficacy, safety and economic effects of various ICIs is a problem that clinicians need to address.MethodsAnalyzed real-world data was collected from non-small cell lung cancer (NSCLC) patients who were treated with ICIs from hospitalized patients in the Lung Cancer Center of Peking Union Medical College Hospital between 2018 and 2021. The objectives were to evaluate the efficacy and safety of different ICIs for the treatment of NSCLC in China and to investigate the factors affecting their curative effects.ResultsOverall, 351 patients were included in the retrospective study. The median PFS for the NSCLC patient cohort treated with medication regimens that included ICIs was 9.5 months, with an ORR of 47.3%. There were no significant discrepancies in efficacy and safety between the different ICIs administered. Factors that had the greatest impact on the efficacy of ICIs were the disease stage, ECOG-PS scores and treatment lines. Gender, age, smoking history, PD-L1 TPS expression, history of targeted therapy and irAEs all had a degree of influence on patient prognosis.ConclusionsThe study reports the experience of real-world usage of ICIs for the treatment of NSCLC patients in China. The results were generally consistent with those of clinical trials, while the efficacy and safety of different ICIs exhibited no statistically significant differences. Therefore, physicians can make a comprehensive choice based on the indications and cost of different ICIs and the preferences of patients.

show abstract

Section: Discussionsupporting

confidence: 91%

Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China

et al. 2022

View full text Add to dashboard Cite

show abstract

“…As expected, rashes and thyroiditis were the two most common irAEs in our cohort. Notably, myositis had a remarkably high incidence rate, while gastrointestinal toxicities were not as common in our cohort, which is different from the setting of NSCLC where interstitial pneumonitis could be more prevalent [ 62 ]. The latter situation has been thought to be related to the cross-immunoreaction to autoantigens mediated with immunotherapy [ 21 , 62 ].…”

Section: Discussionmentioning

confidence: 72%

“…Notably, myositis had a remarkably high incidence rate, while gastrointestinal toxicities were not as common in our cohort, which is different from the setting of NSCLC where interstitial pneumonitis could be more prevalent [ 62 ]. The latter situation has been thought to be related to the cross-immunoreaction to autoantigens mediated with immunotherapy [ 21 , 62 ]. Interestingly, in our cohort, patients who received double immunotherapy were more likely to develop skin, gastrointestinal, and endocrine irAEs.…”

Section: Discussionmentioning

confidence: 72%

Peripheral Blood Biomarkers Predictive of Efficacy Outcome and Immune-Related Adverse Events in Advanced Gastrointestinal Cancers Treated with Checkpoint Inhibitors

Zhang

Xie

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: Gastrointestinal cancers constitute a major burden of global cancer mortalities. In recent years, the advent of immune checkpoint inhibitors has greatly improved the survival of patients with advanced gastrointestinal cancers, while predictive biomarkers of treatment efficacy and toxicities are still unmet demands. Methods: In our retrospective study, patients with advanced gastrointestinal cancers who received single or double immune checkpoint inhibitors in the Department of Gastrointestinal Oncology in Peking University Cancer Hospital between July 2016 and February 2022 were enrolled. Records of clinicopathological information, survival parameters, safety data, and baseline and posttreatment peripheral blood constituents were retrieved. Cox regression analysis and logistic regression analysis were performed to identify the predictive factors of treatment outcomes and immune-related adverse events. Results: We demonstrated that early treatment lines, the presence of immune-related adverse events, and a lower C2 neutrophil-to-lymphocyte ratio were independent factors predicting a superior objective response rate and progression-free survival in patients treated with immunotherapy. Lower ECOG PS, higher baseline albumin, and lower C2 neutrophil-to-lymphocyte ratios were independent risk factors for the onset of immune-related adverse events. Patients who succumbed to immune-related adverse events during immunotherapy presented better survival. Conclusion: Our results indicate that peripheral blood markers have potential for predicting treatment outcomes and immune-related adverse events in patients with advanced gastrointestinal cancer. Prospective validations are warranted.

show abstract

“…Among individuals with irAEs, 5%–10% of the patients treated with ICIs developed checkpoint inhibitor pneumonitis (CIP), resulting in potentially serious toxicity. 13 Similar to other irAEs, low‐grade CIP was found in most cases, and it improved with immunosuppressive therapy. However, severe CIP can lead to fatal respiratory failure.…”

Section: Introductionmentioning

confidence: 75%

Association of immune‐related pneumonitis with clinical benefit of anti‐programmed cell death‐1 monotherapy in advanced non‐small cell lung cancer

Ono

Toi

et al. 2021

Cancer Medicine

View full text Add to dashboard Cite

show abstract

Immune Checkpoint Inhibitor-Related Pneumonitis

Cited by 45 publications

References 96 publications

Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China

Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China

Peripheral Blood Biomarkers Predictive of Efficacy Outcome and Immune-Related Adverse Events in Advanced Gastrointestinal Cancers Treated with Checkpoint Inhibitors

Association of immune‐related pneumonitis with clinical benefit of anti‐programmed cell death‐1 monotherapy in advanced non‐small cell lung cancer

Contact Info

Product

Resources

About